Alcon Laboratories, Inc.

Alcon Manufacturing, Ltd.

Alcon, Inc.

Cognoptix, Inc.

Aldeyra Therapeutics, Inc.

Alcon Pharmaceuticals Ltd.

Novartis Ag

Gerald D Cagle

John M Yanni

David W Stroman

Robert L Abshire

Ole J Lorenzetti

Paul D Hartung

Tai-Lee Ke

Linda L Clark

Celeste H McLean

Barry A Schlech

Mandar V Shah

John Clifford Chabala

Thomas A Jordan

Kerry L Markwardt

Vincent Valvo

Dennis J Nilan

Allan L Rosenthal

Thomas O McDonald

Charles Kerbage

Bahram Asgharian

Francis X Smith

Bhagwati P Kabra

G Michael Wall

Haresh G Bhagat

James E Teague

Rajan Bawa

Rex E Hall

Dennis Nilan

David W Stromann

The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.

Compositions and methods for the treatment of macular degeneration

The present invention relates to a process for preparing an ointment comprising subjecting a mixture of a fluorescent molecular rotor compound, mineral oil, and grinding media to ball milling agitation and combining this mixture with a hydrophobic vehicle for an ointment. The invention also relates to an ophthalmic formulation comprising a pharmaceutically acceptable carrier and a compound of the following structural Formula (I), or a pharmaceutically acceptable salt thereof: Values and preferred values of the variables in structural Formula (I) are described herein.

Methods of preparing ophthalmic formulations and uses of same

In accordance with an embodiment of the invention, there is provided a device and method for detecting an amyloid protein in an eye of a mammal. A method comprises illuminating the eye with a light source having at least one of a wavelength property, a polarization property or a combination thereof, each appropriate to produce fluorescence in at least an amyloid-binding compound when the amyloid-binding compound is bound to the amyloid protein, the amyloid-binding compound having been introduced to the eye and specifically binding to the amyloid protein indicative of the amyloidogenic disorder; and determining a time decay rate of fluorescence for at least the fluorescence produced by the amyloid-binding compound bound to the amyloid protein, the determining permitting distinguishing of the presence of the amyloid-binding compound bound to the amyloid protein in the eye based on at least the time decay rate.

System and method for detecting amyloid proteins

Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.

Compositions containing moxifloxacin for treating otic infections

Method of treating otic infections with moxifloxacin compositions

A surgical knife blade or other surgical device containing an anti-microbial coating. The coating may be adhered to the device by a water-soluble adhesive that allows the anti-microbial coating to be released into the wound track. The coating may be of a consistency that allows a certain amount of the coating to slough off and pool or puddle around the surgical site as the surgical device is moved into and out of the surgical site.

Surgical device includes an anti-microbial coating

Method of treating ophthalmic infections with moxifloxacin compositions

Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues. The compositions and methods of the invention are particularly useful in the treatment of acute otitis externa infections and ophthalmic infections attributable to one or both of two newly identified Microbacterium species, and

Methods for treating otic and ophthalmic infections

Ophthalmic antibiotic compositions containing moxifloxacin

An improved method of sterilizing the field of surgery prior to an ophthalmic surgical procedure is described. The invention eliminates the need for painful and potentially traumatic injections of antibiotics by utilizing sustained release compositions which allow the antibiotics contained therein to penetrate deeply into the eye, thereby ensuring a sterile field of surgery during intraocular surgical procedures. The compositions may also be utilized to prevent post-surgical infections.

Use of sustained release antibiotic compositions in ophthalmic surgical procedures

Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues. The compositions and methods of the invention are particularly useful in the treatment of acute otitis externa infections attributable to one or both of two newly identified Microbacterium species, and

Compositions and methods for treating otic, ophthalmic and nasal infections

The present invention is directed to ophthalmic compositions containing a gelling amount of a combination of galactomannan polysaccharides and borates. The compositions gel or partially gel upon administration to the eye. The present invention also discloses methods of topical ophthalmic administration of the compositions to the eye.

Ophthalmic compositions containing galactomannan polymers and borate

Compositions and methods for treating ophthalmic and otic infections

Growing community of inventors

Fort Worth, TX, United States of America

Gerald D Cagle